---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-129487"
form_type: "8-K"
ticker: "CATX"
cik: "0000728387"
company_name: "Perspective Therapeutics, Inc."
filed_at: "2024-11-21T23:59:59+00:00"
generated_at: "2026-05-29T21:23:56.834727+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Perspective Therapeutics reports positive Phase 1/2a data for [212Pb]VMT-α-NET in NETs; pursuing dose escalation

## Summary
- No dose-limiting toxicities observed at 2.5 and 5.0 mCi doses; safety profile favorable.
- Eight of nine patients had durable disease control; six of nine had measurable tumor reduction, one confirmed RECIST response.
- Safety Monitoring Committee recommends dose escalation to Cohort 3; company to engage with FDA.
- Plans to file IND for PSV359 (FAP-α targeting) by end of 2024.

## SEC filing metadata
- accession: 0000950170-24-129487
- form_type: 8-K
- ticker: CATX
- cik: 0000728387
- company_name: Perspective Therapeutics, Inc.
- filed_at: 2024-11-21T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/728387/000095017024129487/0000950170-24-129487-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/728387/000095017024129487/catx-20241121.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-129487
- JSON: https://secwatch.observer/filing/0000950170-24-129487.json
- Plain text: https://secwatch.observer/filing/0000950170-24-129487.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.